Shuangshuang Mao

Shuangshuang Mao

Auto-generated profile, based on publicly available information

Shuangshuang Mao

Department of Mechanical Engineering, Biomanufacturing Center, Tsinghua University, Beijing 100084, People’s Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2020 in Biofabrication
Verified
Journal Article
Closed access
SMShuangshuang Mao
Shuangshuang Mao
JHJianyu He
Jianyu He
YZYu Zhao
Yu Zhao
TLTiankun Liu
Tiankun Liu
FXFeihu Xie
Feihu Xie
WSWei Sun
Wei Sun
Towards the development of in vivo -mimicking tumor model for extensive study of tumorigenesis and establishment of personalized therapy, patient-derived primary tumor cells were employed in this work for three-dimensional (3D) bioprinting. Intrahepatic cholangiocarcinoma cells isolated from patient were bioprinted using a composite hydrogel system of gelatin-alginate-Matrigel TM into pre-designed grid architecture. ICC cells were observed to process a colony forming ability with high survival rate and active proliferation. Expression levels of tumor markers, cancer stem cell markers, matrix metalloproteinase protein, index of tumor fibrosis, index of liver function, and epithelial-mesenchymal transition regulatory proteins confirmed the development of the invasive and metastatic phenotype of the intrahepatic cholangiocarcinoma cells in the 3D printed tumor microenvironment. Similar results were obtained in anti-cancer drug resistance of the intrahepatic cholangiocarcinoma cells in the 3D bioprinted construct that demonstrated stem-like properties, which suggested the promising potential of current 3D printed tumor model in the development of personalized therapy, especially for discovery of more conducive targeted drugs.

7 July 2020 in Biofabrication
Verified
Journal Article
Closed access
SMShuangshuang Mao
Shuangshuang Mao
Yuan PangYuan Pang
Yuan Pang
TLTiankun Liu
Tiankun Liu
YSYongchun Shao
Yongchun Shao
JHJianyu He
Jianyu He
WSWei Sun
Wei Sun
Studying biological characteristics of tumors and evaluating the treatment effects require appropriate in vitro tumor models. However, the occurrence, progression, and migration of tumors involve spatiotemporal changes, cell–microenvironment and cell–cell interactions, and signal transmission in cells, which makes the construction of in vitro tumor models extremely challenging. In the past few years, advances in biomaterials and tissue engineering methods, especially development of the bioprinting technology, have paved the way for innovative platform technologies for in vitro cancer research. Bioprinting can accurately control the distribution of cells, active molecules, and biomaterials. Furthermore, this technology recapitulates the key characteristics of the tumor microenvironment and constructs in vitro tumor models with bionic structures and physiological systems. These models can be used as robust platforms to study tumor initiation, interaction with the microenvironment, angiogenesis, motility and invasion, as well as intra- and extravasation. Bioprinted tumor models can also be used for high-throughput drug screening and validation and provide the possibility for personalized cancer treatment research. This review describes the basic characteristics of the tumor and its microenvironment and focuses on the importance and relevance of bioprinting technology in the construction of tumor models. Research progress in the bioprinting of monocellular, multicellular, and personalized tumor models is discussed, and comprehensive application of bioprinting in preclinical drug screening and innovative therapy is reviewed. Finally, we offer our perspective on the shortcomings of the existing models and explore new technologies to outline the direction of future development and application prospects of next-generation tumor models.

12 August 2025 in Biofabrication
Verified
Journal Article
Closed access
SMShuangshuang Mao
Shuangshuang Mao
RXRuiyang Xie
Ruiyang Xie
JSJianzhong Shou
Jianzhong Shou
Yuan PangYuan Pang
Yuan Pang
WSWei Sun
Wei Sun
Tumor organoids that can accurately recapitulate the pathophysiological characteristics of original tumor are urgently needed for personalized therapy. However, there are few published studies on patient-derived renal cell carcinoma (RCC) heterogeneous organoids for drug testing to account for patient-specific heterogeneous clinical responses, which has significantly impeded research in the field. Traditional RCC organoid technologies involving matrigel droplets require intensive manual manipulation and are hampered by variability, functional immaturity, low throughput, and limited scale. Here, we applied extrusion-based high-throughput bioprinter to rapidly generate heterogeneous RCC organoids with uniform size, realizing batch automated stable construction and quality control. Bioprinted RCC organoids reserved the pathological morphology and gene mutation/expression characteristics of original tumor and demonstrate interorganoid and interpatient heterogeneity even after long-term cultivation, which are suitable for preclinical patient-specific drug screening testing. Finally, we created multicellular assembloids by reconstituting RCC aggregates with stromal components to generate an organized architecture with in vivo-like vascular morphology and spatial tumor microenvironment heterogeneity. Thus, we have demonstrated the wide-ranging biomedical utility of bioprinted organoids in furthering our understanding of the physiological mechanisms of tumors and the development of personalized treatment methods.